Company release, Inside information,
The Board of Directors of
Antti Vuolanto has acted as the Chief Operating Officer of
"The Board of Directors commenced the CEO recruitment process in January this year. I am very pleased that, after careful evaluation, we found an internal successor within the company who is well equipped to take over the role of CEO. As a result of his management position in the company, Antti Vuolanto has strong experience and knowledge of Herantis' business and strategic development, as well as due to his background, expertise in the company's field of business, research, and product development. Antti has also demonstrated his commitment to the company and its development over the past few years. We thank
"It has been an honour to be closely involved in the development of Herantis and the company's strategy over the last few years and to participate in the important work Herantis is doing in developing disease modifying therapies for Parkinson's Disease. In my new role, I am able to utilize my knowledge of Herantis' industry, business and strategic development, and I am excited about the opportunity to participate in Herantis' next phases in a new role as CEO. I thank the Board of Directors of Herantis for the trust it has shown," says Antti Vuolanto.
The Board of Directors
For more information, please contact:
Tel.: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com
---------------------------------
Certified Advisor:
Company website: www.herantis.com
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit www.herantis.com.
Forward-looking statements
This company release includes forward-looking statements which are not historical facts but statements regarding future expectations instead. These forward-looking statements include without limitation, those regarding Herantis' future financial position and results of operations, the Company's strategy, objectives, future developments in the markets in which the Company participates or is seeking to participate or anticipated regulatory changes in the markets in which the Company operates or intends to operate. In some cases, forward-looking statements can be identified by terminology such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "guidance," "intend," "may," "plan," "potential," "predict," "projected," "should" or "will" or the negative of such terms or other comparable terminology.
By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance and are based on numerous assumptions. The Company's actual results of operations, including the Company's financial condition and liquidity and the development of the industry in which the Company operates, may differ materially from (and be more negative than) those made in, or suggested by, the forward-looking statements contained in this company release. Factors, including risks and uncertainties that could cause these differences include, but are not limited to risks associated with implementation of Herantis' strategy, risks and uncertainties associated with the development and/or approval of Herantis' drug candidates, ongoing and future clinical trials and expected trial results, the ability to commercialize drug candidates, technology changes and new products in Herantis' potential market and industry, Herantis' freedom to operate in respect of the products it develops (which freedom may be limited, e.g., by competitors' patents), the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors.
In addition, even if Herantis' historical results of operations, including the Company's financial condition and liquidity and the development of the industry in which the Company operates, are consistent with the forward-looking statements contained in this company release, those results or developments may not be indicative of results or developments in subsequent periods.
https://news.cision.com/herantis-pharma-oyj/r/antti-vuolanto-appointed-as-ceo-of-herantis-as-of-22-july-2022,c3598918
https://mb.cision.com/Main/18884/3598918/1602614.pdf
(c) 2022 Cision. All rights reserved., source